1. Anon, 2006. Expert Scientific Group on Phase One Clinical Trials: Interim report 20th July 2006: (accessed 29/09/06) 09/6.
2. Aruffo, A., Seed, B., 1987. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proceedings of the National Academy of Sciences U.S.A. 84 8573–8577.
3. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases;Beyersdorf;Annals of Rheumatic Diseases,2005
4. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+ CD25+ regulatory T cells;Beyersdorf;Autoimmunity Reviews,2006
5. Hofstetter, H., Franz, C., Gronen, F., Buttmann, M., Ruprecht, K., Hanke, T. Hünig, T., Toyka, K.V., Rieckmann, P., 2005. The superagonistic monoclonal anti-CD28 antibody modulates cytokine expression in mononuclear blood cells of multiple sclerosis patients and healthy controls. 21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. 10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis. 28.09.2005–01.10.2005.